Literature DB >> 17453175

F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.

Marie-Bernadette Assié1, Laurent Bardin, Agnès Auclair, Nathalie Consul-Denjean, François Sautel, Ronan Depoortère, Adrian Newman-Tancredi.   

Abstract

F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D(2)/D(3) blocking properties and agonist activity at 5-HT(1A) and D(4) receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [(3)H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID(50): 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID(50): 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED(50): 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453175     DOI: 10.1007/s00210-007-0162-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.195


  31 in total

1.  Significant dissociation of brain and plasma kinetics with antipsychotics.

Authors:  Johannes Tauscher; C Jones; G Remington; R B Zipursky; S Kapur
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 2.  DU-127090 Solvay/H Lundbeck.

Authors:  William Wolf
Journal:  Curr Opin Investig Drugs       Date:  2003-01

Review 3.  The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

Authors:  R A Bantick; J F Deakin; P M Grasby
Journal:  J Psychopharmacol       Date:  2001-03       Impact factor: 4.153

4.  In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

Authors:  Marie-Bernadette Assié; Hélène Dominguez; Nathalie Consul-Denjean; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-01       Impact factor: 3.000

Review 5.  Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.

Authors:  Rossella Medori; Erik Mannaert; Gerhard Gründer
Journal:  Eur Neuropsychopharmacol       Date:  2005-12-02       Impact factor: 4.600

Review 6.  Theoretical insights into the mechanism of action of atypical antipsychotics.

Authors:  Adriano B L Tort; Diogo O Souza; Diogo R Lara
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-02-03       Impact factor: 5.067

Review 7.  Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.

Authors:  Gerald A Maguire
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

Review 8.  Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

Authors:  S Kapur; G Remington
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

9.  The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients.

Authors:  Bun-Hee Lee; Yong-Ku Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-02-07       Impact factor: 5.067

10.  Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.

Authors:  Rodrigo A Bressan; Kjell Erlandsson; Hugh M Jones; Rachel Mulligan; Robert J Flanagan; Peter J Ell; Lyn S Pilowsky
Journal:  Am J Psychiatry       Date:  2003-08       Impact factor: 18.112

View more
  1 in total

1.  F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.

Authors:  Marie-Bernadette Assié; Laurent Bardin; Agnès Auclair; Nathalie Consul-Denjean; François Sautel; Ronan Depoortère; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-04-24       Impact factor: 3.195

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.